Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawn Ward

Podiatrist Lima, OH Doctor of Podiatric Medicine

NPI 1114923398 CMS profile 141639

1138 W High St, Lima, OH 45805

Open in the dashboard

General payments

$12,416

159 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawn Ward of Lima, OH is reported in the CMS Open Payments database as having received $12,416 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,885 32
2024 General $884 11
2023 General $969 16
2022 General $2,065 35
2021 General $1,946 9
2020 General $1,789 16
2019 General $2,877 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawn Ward
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Shawn Ward were reported at $1,885. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Shawn Ward Podiatrist median Middle half National median
2019 $2,877 $196 $72–$601 $163
2020 $1,789 $118 $38–$335 $114
2021 $1,946 $169 $57–$573 $132
2022 $2,065 $220 $74–$782 $149
2023 $969 $208 $71–$635 $160
2024 $884 $237 $87–$681 $164
2025 $1,885 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orthofix Medical, Inc. $2,514 35 payments
  2. Arteriocyte Medical Systems, Inc. $1,938 4 payments
  3. Musculoskeletal Transplant Foundation Inc. $1,196 3 payments
  4. Paragon 28, Inc. $908 10 payments
  5. Smith+Nephew, Inc. $762 13 payments
  6. AxoGen $633 10 payments
  7. DePuy Synthes Sales Inc. $632 19 payments
  8. Stryker Corporation $546 11 payments
  9. Bone Support Inc. $366 3 payments
  10. Integra LifeSciences Corporation $361 6 payments
  11. Other $2,559 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,523 138 payments
  2. Travel and Lodging $3,813 19 payments
  3. Consulting Fee $49 1 payment
  4. Gift $32 1 payment
Products named General payments · program years 2019–2025
  1. Magellan $1,671 1 payment
  2. TL-HEX $1,527 14 payments
  3. TrueLok Ring Fixation System $1,267 11 payments
  4. TrueLok $1,000 19 payments
  5. Product Portfolio $705 5 payments
  6. Avance Nerve Graft $402 6 payments
  7. AXOGUARD NERVE PROTECTOR $398 5 payments
  8. AxoGuard Nerve Connector $398 5 payments
  9. CERAMENTBONE VOID FILLER $366 3 payments
  10. CERAMENT G $366 3 payments
  11. Other $8,856 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

357

Median for Podiatry: 160

Drug cost

$12,905

Median for Podiatry: $2,368

Branded share of claims

37.3%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 20 $10,536
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 65 $559
Terbinafine Hcl Generic 42 $436
Gabapentin Generic 18 $283
Doxycycline Hyclate Generic 33 $212
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $186
Clindamycin Hcl Generic 27 $151
Triamcinolone Acetonide Generic 20 $131
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 22 $123
Cephalexin Generic 13 $77

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$85,421

Medicare's payments for the services billed

Medicare patients

252

Average age 74

Services billed

1,232

130 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Diabetes 52%
Ischemic heart disease 48%
Chronic kidney disease 42%
Heart failure 35%
Atrial fibrillation 28%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record